Laurus Labs

Laurus Labs delivered operationally in-line performance, led by healthy traction in CDMO-Synthesis/Non-ARV API segment

India's Laurus Labs Ltd reported a 32.1% rise in third-quarter profit on Monday, boosted by strong demand in its businesses that make chemicals and other ingredients used in medicines

According to the technical analyst from Anand Rathi, Laurus Labs can rally to Rs 400; while RateGain can jump to Rs 330.

One other employee is undergoing treatment in a hospital after the incident that occurred on Monday evening

Laurus has witnessed severe pricing pressure and lower volumes in its ARV formulations portfolio for five quarters now, resulting in significant pressure on core margins, say analyst.

Stocks to Watch: Punjab National Bank (PNB) on Thursday said it received the government's approval to divest its entire stake (15.22 per cent) in UTI Asset Management Company

Despite mixed Q2FY23 performance, brokerages retain their 'buy' rating on Laurus Labs with a target price in the range of Rs 610 and Rs 630 per share.

Drug firm Laurus Labs on Friday said its consolidated net profit increased 14 per cent to Rs 233 crore in the second quarter ended September 30, 2022. The company had reported a net profit of Rs 204 crore in July-September period a year ago. Revenue from operations rose to Rs 1,576 crore in the quarter from Rs 1,203 crore in the year-ago period, Laurus Labs said in a statement. Laurus Labs Founder and CEO Satyanarayana Chava said the results reflect the company's efforts towards strengthening and diversifying its business. He noted that the company has developed a novel delivery for pediatric HIV treatment and expects to file an NDA (new drug application) shortly. "This should significantly enhance our market position. Our capital allocation priorities remain unchanged. We will continue to prioritise investments in our pipeline..," Chava stated. On business outlook, he said, "Looking forward to the second half of 2023, we expect to deliver a strong underlying revenue growth and s

ImmunoACT, backed by Laurus Labs is testing their cancer product

Some of the growth is captured in the price rally, higher valuations

The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.

Analysts remain optimistic on the company's outlook for FY23 & FY24 with new capacity addition for commercial usage for FDF and API segments, ARV business and robust growth expected in CS business.

The company on Thursday said it has received purchase orders from a leading global life sciences company and the supplies will commence from March 2022.

The company said its Q3FY22 results were impacted by lower sales of ARV, APIs and formulations due to stocking at channel partners and it expects improvement from January-March quarter (Q4).

Laurus Labs Ltd, Endurance Technologies Ltd may surge over 30 per cent whereas small cap stocks like Avanti Feeds Ltd, BASF India and Rain Industries could jump up to 40 per cent from current levels

Laurus labs investment in ImmunoACT is part of the larger strategy to strengthen biologics business of the firm

The three stocks are part of several other domestic companies likely to get added to FTSE indices. Adani Transmission is likely to see the largest inflows at $121 million

The management holds a positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio -- and believes the outlook remains robust driven by improving demand and supported by capex

The management maintains positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio-- on the back of improving demand, and supported by capacity expansion plans planned

2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.